Nocturnal non-invasive ventilation (NIV) is an effective treatment for hypercapnic respiratory failure in patients with restrictive thoracic disease. We hypothesized that NIV may reverse respiratory failure by increasing the ventilatory response to carbondioxide (CO 2 ), reducing inspiratory muscle fatigue or enhancing pulmonary mechanics. We studied 20 patients with restrictive disease at baseline (D0) and at 5-8 days (D5) and 3 months (3M). Daytime PaCO 2 reduced from 7.1 ± 0.9 kPa to 6.6 ± 0.8 kPa at D5 and 6.3 ± 0.9 kPa at 3M (p = 0.004), with the hypercapnic ventilatory response increasing from 2.8 ± 2.3 l/min/kPa to 3.6 ± 2.4 l/min/kPa at D5 and 4.3 ± 3.3 l/min/kPa at 3M (p = 0.044). We observed no increase in measures of inspiratory muscle strength including twitch transdiaphragmatic pressure, nor in lung function or respiratory system compliance. These findings suggest that increased ventilatory response to CO 2 is the principal mechanism underlying the long-term improvement in gas-exchange following NIV in patients with restrictive thoracic disease. A new finding is that increases in respiratory muscle strength (sniff oesophageal pressure and sniff nasal pressure) correlated with reductions in Epworth Sleepiness Score, possibly indicating an increase in the ability of patients to activate inspiratory muscles rather than an improvement in contractility.
INTRODUCTION

Domiciliary nocturnal non-invasive ventilation (NIV) is a well-established therapy for
patients with symptomatic, hypercapnic respiratory failure secondary to restrictive thoracic disease. NIV has been shown to alleviate symptoms of headache and daytime somnolence, improve intellectual capacity, 4 reduce hospital admissions, 5 increase exercise tolerance 6 and improve gas exchange. 4, 6, 7 Furthermore, subsequent studies with long-term follow up, have demonstrated that improved gas-exchange and control of symptoms are maintained for up to five years 5, 8 with the majority of patients continuing NIV. In contrast, a study in which NIV was withdrawn from patients established on therapy, led to recurrence of day time somnolence, morning headaches, reduced energy and dyspnea at rest. 9 It is intriguing that a treatment delivered at night should result in an improvement in symptoms and physiological measures during the day. Despite the widespread use of NIV, the mechanism by which ventilatory failure is reversed is not fully understood.
In 1993, Hill proposed three hypotheses by which NIV might work. 10 Firstly, NIV may increase ventilatory sensitivity to CO 2 during spontaneous breathing, secondly it may rest fatigued respiratory muscles so increasing their strength and endurance, and lastly it may improve pulmonary mechanics by increasing compliance and lung volumes. Such changes would improve gas exchange by optimising the load-capacitydrive balance of the respiratory system. A number of studies have assessed these proposed mechanisms in isolation, but few studies have examined all three hypotheses simultaneously 11, 12 making understanding of the inter-relationship between these mechanisms limited. Furthermore, due to their invasive nature and complexity, nonvolitional assessment of respiratory muscle strength (i.e. independent of patient effort) and detailed assessment of respiratory system compliance have not previously been 3 performed in patients with restrictive thoracic disease receiving NIV. Thus the aim of the current study was to investigate these hypotheses concurrently to determine the relative importance of each mechanism.
METHODS
The study was approved by the hospital's ethics committee, and written informed Patients participated in physiological studies at baseline (D0), 5-8 days (D5) and three months after commencing NIV (3M). On each occasion clinical assessment was carried out and symptoms of respiratory failure and subjective sleepiness using the Epworth sleepiness score (ESS) were assessed. Gas-exchange was assessed by measuring daytime arterial blood gases (after 20 minutes rest seated breathing air), overnight pulse oximetry (SaO 2 , pulse oximeter 200-E, Nellcor, Pleasanton, USA) and trans-cutaneous CO 2 (PtcCO 2 , Radiometer A/S, Copenhagen, Denmark).
Ventilator pressures were titrated upwards as tolerated to control nocturnal hypoventilation, by ensuring there was a fall in both peak nocturnal 
RESULTS
Patient characteristics
Of 21 patients approached, 20 took part in the study; 12 had respiratory neuromuscular weakness and 8 kyphoscoliosis. Their characteristics are shown in Table 1 . Three patients with predominant restrictive disease also had co-existing airways obstruction (2 with COPD, and 1 with bronchiectasis). Compared to patients with kyphoscoliosis, those with neuromuscular weakness were significantly heavier with a higher BMI, they had a higher TLC, higher chest wall compliance and lower lung compliance. By definition they had reduced respiratory muscle strength. Table 2 . Three patients were initiated on supplementary oxygen, and their nocturnal SaO 2 values are not included. There was a trend towards a reduction towards start of night PtcCO 2 and no significant reduction in peak PtcCO 2 . There was a significant reduction in both the nadir SaO 2 and the proportion of the night spent with an SaO 2 less than 90%. 
Ventilatory response to carbon-dioxide
Following NIV there was a significant increase in HCVR from 2.8 ± 2.3 l/ min/ kPa at D0 to 3.6 ± 2.4 at D5 and 4. 
Respiratory muscle strength
Measures of respiratory muscle strength are illustrated in Figure values of compliance at D0, D5 and 3M are shown in Table 3 . 
Comparisons between neuromuscular weakness and kyphoscoliosis
Larger sample sizes would be required for meaningful statistical comparison between the patients with neuromuscular weakness and kyphoscoliosis. Our data, however, does not suggest any differences in response to NIV between the two sub-groups, with respect to hours of use, changes in arterial blood gases, drive or muscle strength.
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Relationship between physiological changes and subjective sleepiness
There was a significant relationship between the fall in ESS and hours of use at 3M as 
Critique of the method
Study design
It would have been preferable for patients to undergo a standardized run-in period for optimisation of medical therapy before commencing NIV, and to have a matched control group who had similar medical contact time and support without NIV.
However, this was not possible for logistical and ethical reasons. In particular it
would have been difficult to admit patients to hospital without offering NIV.
Furthermore it was not considered ethical to delay treatment of the patients for three months following assessment. All patients were referred for NIV by external respiratory specialists, and had undergone optimisation of medical therapy prior to entry in to the study.
Test reproducibility
HCVR
There is a high degree of intrinsic variability in HCVR. This was minimised by using the mean of two tests, and carrying out testing at the same time of day by the same investigator in a quiet room. In 30 patients with respiratory failure studied on two occasions in our laboratory there was no significant difference in HCVR between the first and second tests (2.51 ± 2.91 and 2.65 ± 2.63 l/ min/ kPa respectively, p = 0.78).
Respiratory muscle strength
In our laboratory there is good long term reproducibility of Sniff Pdi and TwPdi with follow up over 1 to 5 years in healthy volunteers, 15 and over 1 week to 10 months in patients with normocapnic moderate to severe COPD 16 . To our knowledge there has not been a study of sequential measurement of TwPdi patients with severe chest wall deformity, and abnormal anatomy of the cervical region. Reasonable reproducibility is suggested by the much greater inter-than intra-subject variability on repeat testing at D0, D5 and 3M. Values of TwPdi were small however, and any genuine physiological changes may have been beyond the resolution of the test.
Respiratory compliance
We have demonstrated in our laboratory that static lung and chest wall compliance measurements are useful in identifying physiological differences between diagnostic groups, however it is possible that this technique is not sufficiently sensitive to detect small within subject changes. Despite this, the absence of changes in lung volumes makes it unlikely that significant changes in compliance occurred.
Significance of findings
Use and efficacy of NIV In our patient group NIV resulted in a significant improvement in daytime arterial blood gases and a reduction in subjective sleepiness. In contrast to most previous studies, we did not exclude patients with combined restrictive and obstructive ventilatory defects because such patients are common in clinical practice. Our patient group is therefore likely to include individuals who are more challenging to ventilate successfully, but perhaps to be more representative of the wider population of patients with respiratory failure. Greater NIV use at D5 than 3M may reflect several factors: in the early days in hospital there may be greater patient motivation due to high expectations of a new therapy and intensive support from the multi-disciplinary team.
In addition, nurses may select the start and end times of NIV use. Later on at home NIV use may reduce as patients determine the optimal balance between symptomatic benefit and NIV tolerability for them.
Increased ventilatory sensitivity to CO 2 HCVR increased significantly following NIV. Such an increase in the ventilatory response to CO 2 enables a more appropriate increase in ventilation to occur in response to transient increases in PaCO 2 , so diminishing hypercapnia. It is likely that the increase in HCVR is brought about by reduced renal retention of bicarbonate, so reducing acid buffering capacity. In this way chemoreceptors could be 'reset' to become responsive at a lower level. The increase in HCVR appeared to be directly attributable to an increase in central ventilatory drive rather than to 'unmasking' of drive, since it occurred independently of changes in lung volumes, respiratory muscle strength or compliance. It is of course also possible that the improvement in HCVR is due to a small increase in capacity and reduction in load, which in isolation are not significant, but in combination have a much larger effect. Multiple linear regression of measures of capacity and load with HCVR were not significant, however our study was not powered to examine this relationship. Our findings are similar to those of Annane and coworkers 11 but not to those of Dellborg and coworkers 12 . This may be attributable to the fact that patients in this latter study had a higher baseline HCVR at 3.8 l/ min/ kPa, compared to 2.9 l/ min/ kPa in our own study.
There was a non-significant trend for the increase in HCVR to be associated with a decrease in PaCO 2 in compliant patients at 3 months. This suggests that PaCO 2 may be determined in part by the ventilatory response to CO 2 , but is likely to also be dependent on other factors. This is not surprising, since even when HCVR is increased by over 50% at 3M, it is still markedly sub-normal compared to healthy controls, enabling PaCO 2 to fluctuate, albeit around a lower mean value than prior to initiation of NIV. The relationship between HCVR and PaCO 2 is also weakened by the intrinsic variability of both these measures. Annane and coworkers found a significant relationship between changes in HCVR and PaCO 2 following NIV, 11 however their analysis was carried out in a different way: repeated testing was carried out at 6 months, 1, 2, and 3 years and the maximum change for each individual was used, rather than all data at a given time interval. Our data was not analysed in this way, as it might have introduced a more favourable bias, rather than giving a true reflection of the changes at a given time interval. Dellborg and coworkers 12 found no correlation between changes in HCVR and PaCO 2 .
Changes in respiratory muscle strength
The second hypothesis regarding the mechanism of action of NIV is that hypercapnic respiratory failure is associated with respiratory muscle fatigue, and that NIV provides muscle rest, so relieving fatigue and increasing muscle strength. We found a significant increase in only one measure of strength, PeMax. Reports of changes in muscle strength in the literature are variable, with some finding no difference in muscle strength 11 and others isolated increases in single measures 12 .
To our knowledge, ours is the first study to investigate a non-volitional measure of respiratory muscle strength, and it is of interest that there was no change in TwPdi. To our knowledge, ours is also the first study to examine the relationship between changes in muscle strength and subjective sleepiness. Although the ESS has not been formally validated in patients with hypercapnic respiratory failure, previous investigators have observed it to fall in this patient group following NIV 19 . We found a significant correlation (sniff Poes and SNIP) and trend towards correlation (sniff Pdi showing an increased ability to activate the respiratory muscles rather than improved contractility per se. This could arise due to a greater sense of 'well-being', enabling more effort to be applied. Against this, however, Hill and coworkers 9 found no decrements in respiratory muscle strength following withdrawal of NIV from patients established on it for respiratory failure despite a recurrence of somnolence. It may be that in some way central facilitation occurs following NIV, enabling patient's effort to be more effectively translated into force.
In this study we did not assess changes in respiratory muscle endurance following NIV, which may be more relevant to sustained respiratory effort in the face of increased respiratory load than respiratory muscle strength. One study has previously examined this relationship, and suggested that endurance was increased following NIV. 23 Optimisation of pulmonary mechanics
The final hypothesis regarding the mechanism of action of NIV in restrictive disease is that pulmonary mechanics in hypercapnic respiratory failure are disadvantaged due to both chronic hypoventilation and distortion of the thoracic cage, leading to an increase in work of breathing, and that NIV reverses some of these changes so tending to restore the balance between capacity and load of the respiratory system. In our study there was no change in spirometry, lung volumes or carbon monoxide transfer factor following NIV. This enables us to be confident that changes in other parameters that may be dependent on lung volume, such as inspiratory muscle strength and HCVR occurred as primary effects, and were not merely secondary to changes in pulmonary mechanics. Our findings are in keeping with most previous studies 7, 11, 17, 18, 24 . Dellborg and coworkers 12 observed a small but statistically significant increase in vital capacity from 1.2 to 1.3 l, the clinical significance of which is not entirely clear.
In the current study no significant changes in static compliance were observed in the group as a whole or in sub-groups of patients, however it is interesting to note that there was a greater numerical increase in static lung compliance in patients with neuromuscular weakness and greater numerical increase in static chest wall compliance in patients with kyphoscoliosis. It is likely that numbers of patients were too small to demonstrate significant differences within the sub-groups. In addition, the reproducibility of static lung compliance in patients with critically compromised respiratory function may be insufficient to detect small changes. Simonds and coworkers 25 have previously compared intermittent hyperinflation for 5 minutes 2-3 times a day for 3 months using either volume-or pressure-preset ventilation in patients with kyphoscoliosis. They found volume but not pressure-preset ventilation resulted in a significant increase in vital capacity. Since respiratory muscle strength remained unchanged, this was thought to be due to an increase in compliance of the respiratory system. The improvement with volume but not pressure-preset ventilation was thought to be due to the higher inspiratory pressures achieved (33 and 30 cmH 2 O respectively). In our study, the mean inspiratory pressure used was 21 cmH 2 O (22 cmH 2 O for patients with neuromuscular weakness and 20 for patients with kyphoscoliosis). It seems likely that higher inflation pressures and transient hyperinflation is necessary to increase respiratory system compliance.
Conclusions
In conclusion, this study confirms NIV to be an effective treatment in patients with symptomatic hypercapnic respiratory failure secondary to restrictive disease alone, both in terms of daytime CO 2 and sleepiness. It supports the hypothesis that NIV reverses ventilatory failure by increasing the ventilatory response to CO 2 . 
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